VG Life Sciences (OTCMKTS:VGLS – Get Rating) and Longeveron (NASDAQ:LGVN – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.

Profitability

This table compares VG Life Sciences and Longeveron's net margins, return on equity and return on assets.

Risk & Volatility

VG Life Sciences has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.

Analyst Ratings

Longeveron has a consensus target price of $13.25, suggesting a potential upside of 231.25%.

Institutional and Insider Ownership

2.1% of Longeveron shares are owned by institutional investors. 41.6% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares VG Life Sciences and Longeveron's gross revenue, earnings per share (EPS) and valuation.

VG Life Sciences has higher earnings, but lower revenue than Longeveron.

About VG Life Sciences

(Get Rating)

VG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers. In addition, it offers targeted peptide technology (TPT), a technology that eliminates the subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. VG Life Sciences Inc. was formerly known as Viral Genetics Inc. and changed its name to VG Life Sciences Inc. in November 2012. The company was founded in 1995 and is based in Santa Barbara, California. VG Life Sciences Inc. operates as a subsidiary of Feelux Co., Ltd.

About Longeveron

(Get Rating)

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Receive News & Ratings for VG Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VG Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.